PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 144 filers reported holding PROGENICS PHARMACEUTICALS IN in Q2 2019. The put-call ratio across all filers is 0.54 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $3,528,000 | -30.2% | 928,279 | -6.6% | 0.00% | 0.0% |
| Q4 2019 | $5,058,000 | -11.4% | 993,659 | -12.1% | 0.00% | -50.0% |
| Q3 2019 | $5,712,000 | -21.0% | 1,130,093 | -3.5% | 0.00% | 0.0% |
| Q2 2019 | $7,226,000 | +33.8% | 1,171,273 | +0.7% | 0.00% | 0.0% |
| Q1 2019 | $5,400,000 | +11.1% | 1,163,699 | +0.6% | 0.00% | 0.0% |
| Q4 2018 | $4,859,000 | -33.2% | 1,156,879 | -0.3% | 0.00% | 0.0% |
| Q3 2018 | $7,277,000 | -14.8% | 1,160,542 | +9.2% | 0.00% | 0.0% |
| Q2 2018 | $8,546,000 | +10.3% | 1,062,981 | +2.3% | 0.00% | 0.0% |
| Q1 2018 | $7,750,000 | +25.2% | 1,038,908 | -0.2% | 0.00% | 0.0% |
| Q4 2017 | $6,192,000 | -20.5% | 1,040,628 | -1.7% | 0.00% | 0.0% |
| Q3 2017 | $7,791,000 | +7.1% | 1,058,604 | -1.2% | 0.00% | 0.0% |
| Q2 2017 | $7,277,000 | -29.8% | 1,071,824 | -2.4% | 0.00% | -33.3% |
| Q1 2017 | $10,370,000 | +110.0% | 1,098,566 | +92.2% | 0.00% | +200.0% |
| Q4 2016 | $4,939,000 | +45.3% | 571,661 | +6.4% | 0.00% | 0.0% |
| Q3 2016 | $3,400,000 | +44.1% | 537,130 | -3.9% | 0.00% | 0.0% |
| Q2 2016 | $2,360,000 | -2.8% | 559,054 | +0.4% | 0.00% | 0.0% |
| Q1 2016 | $2,427,000 | -28.7% | 556,697 | +0.2% | 0.00% | 0.0% |
| Q4 2015 | $3,404,000 | -6.9% | 555,360 | -13.1% | 0.00% | 0.0% |
| Q3 2015 | $3,657,000 | -8.2% | 639,160 | +19.7% | 0.00% | 0.0% |
| Q2 2015 | $3,985,000 | +40.2% | 534,086 | +12.3% | 0.00% | 0.0% |
| Q1 2015 | $2,843,000 | -21.4% | 475,377 | -0.7% | 0.00% | 0.0% |
| Q4 2014 | $3,618,000 | +89.3% | 478,586 | +29.9% | 0.00% | 0.0% |
| Q3 2014 | $1,911,000 | -32.7% | 368,302 | -44.0% | 0.00% | – |
| Q2 2014 | $2,838,000 | +92.7% | 658,250 | +82.8% | 0.00% | – |
| Q1 2014 | $1,473,000 | -8.7% | 360,093 | +18.9% | 0.00% | – |
| Q4 2013 | $1,613,000 | -51.1% | 302,749 | -53.9% | 0.00% | – |
| Q3 2013 | $3,296,000 | +168.4% | 656,250 | +138.4% | 0.00% | – |
| Q2 2013 | $1,228,000 | – | 275,232 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Phocas Financial Corp. | 1,033,328 | $6,376,000 | 0.68% |
| ARDSLEY ADVISORY PARTNERS LP | 650,000 | $4,011,000 | 0.63% |
| Worth Venture Partners, LLC | 138,357 | $853,000 | 0.47% |
| RICE HALL JAMES & ASSOCIATES, LLC | 2,242,503 | $13,836,000 | 0.46% |
| HIGHLAND CAPITAL MANAGEMENT LP | 716,880 | $4,423,000 | 0.26% |
| FARALLON CAPITAL MANAGEMENT LLC | 5,543,386 | $34,203,000 | 0.22% |
| Point72 Asset Management, L.P. | 5,858,749 | $36,148,000 | 0.19% |
| PINNACLE ASSOCIATES LTD | 1,298,723 | $8,013,000 | 0.19% |
| Fosun International Ltd | 472,580 | $2,750,000 | 0.18% |
| J. Goldman & Co LP | 400,000 | $2,468,000 | 0.17% |